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Aim: To report the results of a 104-week extension to a 52-week study in which
dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and
metabolic variables compared with glimepiride (GLIM) in participants with type 2 dia-
betes (T2D) receiving background metformin.
Materials and methods: This extension to a 52-week global, multicentre, parallel-
group, active-controlled, double-blind study (NCT02419612) continued randomized
participants (1:1) on DAPA+SAXA (10/5 mg) plus placebo, or GLIM (1-6 mg) plus pla-
cebo, once daily. Eligible participants were aged ≥18 years, had T2D (glycated
haemoglobin [HbA1c] 58.5-91.3 mmol/mol [7.5%-10.5%]), and a body mass index of
20.0 to 45.0 kg/m2, and were receiving metformin (MET; ≥1500 mg/d). Key out-
comes were: requirement for treatment intensification, based on HbA1c ≥53 mmol/
mol (7%); achieving therapeutic glycaemic response; and changes in adipose tissue
and liver fat on magnetic resonance imaging in a substudy.
Results: Overall, 382 participants entered and 338 completed the 104-week exten-
sion period (MRI substudy, n = 82). The need for treatment intensification during the
156-week period was lower for DAPA+SAXA+MET (37.0%) than GLIM+MET
(55.6%; hazard ratio 0.52, 95% confidence interval [CI] 0.39-0.68; P < 0.001). At
week 156, 21.4% of DAPA+SAXA+MET versus 11.7% of GLIM+MET participants
achieved therapeutic glycaemic response (HbA1c <53 mmol/mol; odds ratio 2.1, 95%
CI 1.23-3.42; P = 0.006). DAPA+SAXA+MET led to greater adjusted mean reduc-
tions from baseline in liver fat and visceral and subcutaneous adipose tissue volumes
versus GLIM+MET at week 122 (least-squares mean difference from GLIM+MET
4.89%, 0.41 L and 0.44 L, respectively; nominal P values ≤ 0.008). Safety was
consistent with that of the monocomponents.
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Conclusions: Overall, glycaemic control, metabolic benefits and efficacy were better
maintained with DAPA+SAXA+MET than with GLIM+MET in T2D.
K E YWORD S
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1 | INTRODUCTION
Despite the availability of multiple classes of glucose-lowering drugs,
the progressive nature of type 2 diabetes (T2D) makes maintenance
of glycaemic control difficult.1 Metformin (MET) is the preferred initial
pharmacological treatment, with stepwise addition of glucose-
lowering drugs recommended if glycaemic targets are not acheived.2
Because clinical inertia often leads to delays in achieving glycaemic
goals, therapies that provide rapid control with durability over time
are needed. Moreover, T2D is associated with nonalcoholic fatty liver
disease (NAFLD)3; therefore, assessing the effect of treatment on liver
fat and other metabolic variables, in addition to glycaemic control, is
of considerable interest.
American Diabetes Association (ADA) guidance advocates consid-
eration of initial combination therapy for patients with significantly
elevated glycated haemoglobin (HbA1c) levels (1.5%-2% above tar-
get).2 Sodium-glucose cotransporter-2 (SGLT2) inhibitors and
dipeptidyl peptidase-4 (DPP-4) inhibitors are recommended as
second-line therapies for T2D management.2 The ADA also recom-
mends SGLT2 inhibitors irrespective of HbA1c levels in patients with
established atherosclerotic cardiovascular disease, kidney disease or
heart failure.2 Dapagliflozin (DAPA), a selective SGLT2 inhibitor,
reduces fasting plasma glucose (FPG) levels, HbA1c levels, systolic
blood pressure (SBP) and body weight in patients with T2D.4
Saxagliptin (SAXA), a selective DPP-4 inhibitor, reduces HbA1c levels,
with neutral effects on body weight.4 Both drugs also have a low risk of
causing hypoglycaemia, especially when compared with sulphonylureas.4
The addition of DAPA in combination with SAXA to MET has been
shown to have superior efficacy to that of either of the individual medica-
tions plus MET from 24 to 52 weeks of treatment.5-9
The optimal pharmacological approach for achieving and
maintaining glycaemic targets is currently unknown, but some evi-
dence suggests that early intensive treatment with a combination of a
DPP-4 inhibitor and MET may be more beneficial than sequential
addition of a DPP-4 inhibitor when MET monotherapy fails to main-
tain glycaemic control.10 However, more evidence is needed to help
determine whether the durability of glycaemic response and meta-
bolic benefits can be maintained over the long term. Add-on therapy
with a sulphonylurea can be considered for stepwise treatment inten-
sification, particularly in patients for whom medication cost is a con-
cern, although disadvantages include weight gain, increased risk of
hypoglycaemia11 and poor durability of glycaemic response.12
In a 52-week study, DAPA in combination with SAXA was previously
evaluated as an add-on to MET in comparison with the sulphonylurea
glimepiride (GLIM) plus MET in participants with T2D inadequately
controlled on MET monotherapy.13 DAPA+SAXA+MET (compared with
GLIM+MET) was associated with significantly greater adjusted mean
reductions from baseline at week 52 in HbA1c (least-squares [LS] mean
change 1.35%, 95% confidence interval [CI] 1.49, 1.22 vs. 0.98%,
95% CI 1.12, 0.84), body weight and SBP, with 1.5 times greater odds
of achieving a therapeutic glycaemic response of HbA1c <53.0 mmol/mol
(7.0%) at 52 weeks, and with a lower proportion of participants requiring
treatment intensification (addition of insulin or other glucose-lowering
drug for rescue therapy, or discontinuation for lack of glycaemic control –
defined as an HbA1c level ≥ 53.0 mmol/mol [7.0%]) during the 52-week
treatment period.13 A magnetic resonance imaging (MRI) substudy found
greater adjusted mean decreases in liver fat and adipose tissue volumes
from baseline at week 52 with DAPA+SAXA+MET versus GLIM+MET
treatment.14
In the present paper, we report the results of the 104-week
extension to the 52-week study, as well as the 122-week results of
the MRI substudy.
2 | METHODS
2.1 | Study design and participants
This was a 52-week, global, multicentre, randomized, parallel-group,
double-blind, active-controlled, phase 3b study,13,14 with a site- and
participant-blinded 104-week extension period (Figure S1). The study
was conducted from August 2015 to September 2019 at 88 centres in
10 countries (United States, Hungary, Romania, Poland, Mexico, Russia,
the Czech Republic, Sweden, Germany and the United Kingdom).
Eligible participants entered a 2-week screening and a 2-week
lead-in period. Men and women (aged ≥18 years) with T2D, HbA1c
levels of 58.5 to 91.3 mmol/mol (7.5%-10.5%; inclusive) and body
mass index (BMI) of 20.0 to 45.0 kg/m2 (inclusive) at the enrolment
visit, who were currently treated with MET and on a stable dose
(≥1500 mg/d) for ≥8 weeks before enrolment, were eligible for inclu-
sion. Additional inclusion/exclusion criteria information can be found
in Appendix S1 and in the the 52-week data publications.13,14
2.2 | Ethics
The study followed regulatory requirements, including the sponsor's
policy on bioethics, and was performed in accordance with the Decla-
ration of Helsinki and the International Council for Harmonisation
Good Clinical Practice guidelines. The local independent ethics
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committees/institutional review boards approved the final protocol
and any amendments. All participants provided written informed con-
sent prior to inclusion in the study and MRI substudy.
2.3 | Randomization and masking
Participants receiving MET were randomized in a 1:1 ratio to receive
double-blinded once-daily DAPA 10 mg plus once-daily SAXA 5 mg
plus placebo or once-daily titratable GLIM 1 to 6 mg (starting at 1 mg
and titrated at 3-week intervals up to week 12 to a maximum of 6 mg
using stepwise doses of 2, 3, 4 and 6 mg) plus placebo. GLIM could be
downtitrated in case of hypoglycaemia. Randomization, stratified by
site, was performed via an interactive voice response system that
assigned each participant a unique, sequential five-digit number.
Treatment with thiazolidinediones, glucagon-like peptide-1 receptor
agonists, sulphonylureas and DPP-4 inhibitors or SGLT2 inhibitors
other than the investigational drugs was not allowed.
Participants were rescued for hyperglycaemia with open-label
insulin or, if not appropriate, other drugs except a DPP-4 inhibitor,
SGLT2 inhibitor or sulphonylurea. Up-to-week-52 rescue criteria were
based on FPG values,13 whereas after-week-52 rescue was under-
taken if the HbA1c level was >58.5 mmol/mol (7.5%).
2.4 | MRI substudy
As previously reported,14 the MRI substudy included participants from
the full study who had a BMI of 20.0 to 40.0 kg/m2 (inclusive) at
enrolment, a maximum weight of 140 kg to accommodate MRI scan-
ning and no other contraindications to MRI scanning.
Participants assigned to the MRI substudy had an ad hoc visit to the
imaging site within 2 weeks prior to the randomization visit, within
±2 weeks of the week-52 visit and within ±4 weeks of the week-122
visit. Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT)
volumes were assessed using abdominal MRI. Liver fat content was
assessed using MRI-estimated proton density fat fraction (PDFF).
2.5 | Study objectives and assessments
Secondary endpoints for the overall 156-week study were: time to
treatment intensification during the 156-week treatment period, and
proportion of participants achieving a therapeutic glycaemic response
at week 156.
All other objectives were exploratory and included mean changes
from baseline in HbA1c, FPG, SBP, total body weight and serum alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) levels for all
participants assessed at week 156. Other exploratory endpoints included
the mean time spent at or below HbA1c 53.0 mmol/mol (7.0%) over
156 weeks, the proportion of participants achieving a therapeutic
glycaemic response without any hypoglycaemia at week 156 and the pro-
portion of participants achieving a therapeutic glycaemic response
without any hypoglycaemia and without any weight gain at week 156.
Participants rescued or discontinued prior to and participants with missing
measurements at the specified timepoint were treated as nonresponders.
In the MRI substudy, endpoints included mean changes from baseline
in liver fat percentage and SAT and VAT volumes at weeks 52 and 122.
Post hoc analyses of mean changes from baseline for HbA1c, serum ALT
and AST levels, body weight, and fibrosis-4 (FIB-4) scores were assessed
over the 156-week treatment period for this substudy.
2.6 | Statistical analyses
Sample size calculations and other statistical analysis details can be
found in the 52-week study and MRI substudy publications.13,14
Efficacy analyses during the 156-week treatment period included
two secondary endpoints (part of sequential statistical testing13) and
exploratory endpoints. Time to treatment intensification was tested
before the proportion of participants achieving a therapeutic glycaemic
response and was analysed using a Cox proportional hazards model and
censored at 156 weeks if treatment intensification had not occurred by
this timepoint. Participants rescued at the end of the treatment period
were counted as having an event. The proportion of participants achiev-
ing a therapeutic glycaemic response at week 156 was analysed using
logistic regression adjusting for baseline HbA1c. Participants rescued, dis-
continued prior to or with missed measurements at week 156 were con-
sidered as not achieving a glycaemic response (ie, nonresponders).
Exploratory change-from-baseline endpoints used a mixed model
of repeated measures, which assumes that data are missing at ran-
dom, including terms for treatment, baseline result, visit, treatment-
by-visit interaction and baseline result-by-visit interaction, with no
multiplicity adjustments and nominal P values presented. Efficacy
results were summarized prior to rescue and treatment discontinua-
tion (plus a tolerance window after the last dose). For HbA1c and
body weight, assessments collected after initiation of rescue medica-
tion or collected >8 days after the last dose in the 156-week treat-
ment period were excluded from the analysis. For lipids and SBP,
>4 days was used, whereas for FPG >1 day was used.
Time spent at or below the HbA1c target (HbA1c ≤53 mmol/mol
[7.0%]) over the 156-week treatment period was calculated for each
participant using linear interpolation and analysed using an analysis of
covariance model including terms for treatment and baseline HbA1c.
Safety data were summarized descriptively regardless of rescue
medication (hypoglycaemic events summarized prior to rescue medi-
cation), and results >4 days after the last dose were excluded (30 days
for serious adverse events [AEs] and liver function tests).
Statistical analyses were performed with SAS version 9.4 (SAS
Institute Inc.).
3 | RESULTS
In the main 52-week study, 444 participants were randomized
(443 received treatment) and 385 completed the double-blind
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treatment period.13 Overall, 382 participants entered the 104-week
long-term extension period, of whom 338 completed the extension
period and 318 completed treatment during the extension period
(Figure S2). A total of 82 participants who gave consent to have MRI
performed were included in the randomized MRI substudy (46 in the
DAPA+SAXA+MET group and 36 in the GLIM+MET group).
Treatment groups for the full study (Table 1) and the MRI sub-
study (Table S1) were proportionally well balanced with regard to
demographics, participant characteristics and disease characteristics.
Mean treatment compliance during the 156-week treatment period
was 99% in both groups.
3.1 | Full study
There were 84/227 participants (37.0%) in the DAPA+SAXA+MET
group and 120/216 participants (55.6%) in the GLIM+MET group
who required treatment intensification by week 156. Figure 1 shows
a Kaplan-Meier plot of the time to treatment intensification during
the 156-week treatment period. There was a 48% decreased risk of
treatment intensification during the 156-week treatment period for
participants in the DAPA+SAXA+MET group compared with partici-
pants in the GLIM+MET group (hazard ratio 0.52 [95% CI 0.39, 0.68];
P < 0.001).
Table S2 shows the data for participants who were rescued dur-
ing the 156-week treatment period and the rescue medications taken.
The most common rescue treatment was insulin (49 participants
[21.6%] in the DAPA+SAXA+MET group and 71 participants [32.9%]
in the GLIM+MET group).
Table S3 shows the proportion of participants achieving a thera-
peutic glycaemic response (HbA1c <53.0 mmol/mol [7.0%]) at week
156. At week 156, 21.4% of participants in the DAPA+SAXA+MET
group versus 11.7% of participants in the GLIM+MET group achieved
a therapeutic glycaemic response (odds ratio 2.1 [95% CI 1.23, 3.42];
P = 0.006).
Figure 2 presents the adjusted mean change from baseline in
HbA1c through to week 156. Table S4 shows additional exploratory
efficacy analysis results for the 156-week treatment period. The pro-
portion of participants in the DAPA+SAXA+MET group who achieved
a therapeutic glycaemic response without any hypoglycaemia was
TABLE 1 Demographics and baseline disease characteristics (randomized analysis set)
DAPA+SAXA+MET (N = 227) GLIM+MET (N = 216) Total (N = 443)
Age, years 56.1 (10.1) 56.1 (9.2) 56.1 (9.7)
Female, n (%) 110 (48.5) 115 (53.2) 225 (50.8)
Weight, kg 91.0 (19.8) 88.4 (17.1) 89.7 (18.5)
BMI, kg/m2 32.4 (5.3) 32.2 (5.1) 32.3 (5.2)
BMI group, n (%)
<25 kg/m2 13 (5.7) 14 (6.5) 27 (6.1)
≥25 kg/m2 214 (94.3) 202 (93.5) 416 (93.9)
≥27 kg/m2 191 (84.1) 186 (86.1) 377 (85.1)
≥30 kg/m2 145 (63.9) 136 (63.0) 281 (63.4)
Race, n (%)
White 206 (90.7) 196 (90.7) 402 (90.7)
Black or African American 4 (1.8) 5 (2.3) 9 (2.0)
American Indian or Alaska Native 11 (4.8) 10 (4.6) 21 (4.7)
Othera 6 (2.6) 5 (2.3) 11 (2.5)
Region, n (%)
North America 57 (25.1) 55 (25.5) 112 (25.3)
Latin America 39 (17.2) 37 (17.1) 76 (17.2)
Europe 131 (57.7) 124 (57.4) 255 (57.6)
Duration of T2D, years 7.7 (6.4) 7.9 (6.5) 7.8 (6.4)
HbA1c, % 8.4 (0.8) 8.5 (0.8) 8.5 (0.8)
FPG, mg/dL 172.9 (41.5) 176.5 (42.4) 174.7 (41.9)
Note: The randomized analysis set comprised all randomized participants who received ≥1 dose of the double-blinded study drug during the 52-week
treatment period. Participants were included in the treatment group to which they were randomized at the start of the 52-week treatment period. Data
are mean (SD), unless otherwise indicated.
Abbreviations: BMI, body mass index; DAPA, dapagliflozin; FPG, fasting plasma glucose; GLIM, glimepiride; HbA1c, glycated haemoglobin; MET,
metformin; SAXA, saxagliptin; SD, standard deviation; T2D, type 2 diabetes.
aIncludes Asian, Native Hawaiian or other Pacific Islander and Other.
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F IGURE 1 Time to treatment intensification during the 156-week treatment period, Kaplan-Meier plot (randomized analysis set). Treatment
intensification was defined as addition of insulin or other glucose-lowering agents for rescue therapy or discontinuation for lack of glycaemic
control. Time to treatment intensification was censored at 156 weeks if treatment intensification had not occurred by then. Participants rescued
at week 156 were counted as having an event for the analysis. “j” and “0” denote a censored observation. DAPA, dapagliflozin; GLIM,
glimepiride; MET, metformin; N, number of participants in the treatment group; r, number of participants at risk at that timepoint; SAXA,
saxagliptin
F IGURE 2 Adjusted mean change from baseline in glycated haemoglobin (HbA1c) up to week 156, prior to rescue and treatment
discontinuation (randomized analysis set). Repeated measures analysis, least-squares mean (95% confidence interval [CI]). Participants with
nonmissing baseline assessment and ≥1 post-baseline assessment were included in the analysis. (DAPA+SAXA+MET, 218; GLIM+MET, 212).
Week 0 refers to the baseline value. Baseline is defined as participants in the randomized analysis set with nonmissing baseline assessment
and ≥1 post-baseline assessment. DAPA, dapagliflozin; GLIM, glimepiride; MET, metformin; N, number of participants in the treatment group; n,
number of participants with observed result at a timepoint; SAXA, saxagliptin
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TABLE 2 Selected AEs during the 156-week treatment period (treated participants dataset)
DAPA+SAXA+MET (N = 227) GLIM+MET (N = 216)
Regardless of rescue
Total participants by AE category,a n (%)
≥1 AE 180 (79.3) 179 (82.9)
≥1 hypoglycaemic eventb 54 (23.8) 120 (55.6)
≥1 AE or hypoglycaemic eventb 188 (82.8) 191 (88.4)
≥1 AE causally related to IP 41 (18.1) 20 (9.3)
Any AE with outcome of death 1 (0.4) 3 (1.4)
≥1 SAE 29 (12.8) 24 (11.1)
≥1 SAE causally related to IP 3 (1.3) 1 (0.5)
SAE leading to discontinuation of IP 2 (0.9) 8 (3.7)
AE leading to discontinuation of IP 13 (5.7) 13 (6.0)
Hypoglycaemia leading to
discontinuation of IP
1 (0.4) 1 (0.5)
UTI AEs of special interestc
Men
N 117 101
Participants with any AE of UTI, n (%) 11 (9.4) 7 (6.9)
UTIs 7 (6.0) 7 (6.9)
Cystitis 3 (2.6) 0
Urethritis 1 (0.9) 0
Women
N 110 115
Participants with any AE of UTI, n (%) 29 (26.4) 17 (14.8)
UTIs 25 (22.7) 14 (12.2)
Cystitis 2 (1.8) 4 (3.5)
Escherichia UTIs 1 (0.9) 0
Urogenital infection fungal 1 (0.9) 0
Prior to rescue
Total participants with hypoglycaemic
events, n (%)
51 (22.5) 103 (47.7)
Severe hypoglycaemia 0 3 (1.4)
Documented symptomatic
hypoglycaemia
19 (8.4) 53 (24.5)
Asymptomatic hypoglycaemia 39 (17.2) 82 (38.0)
Probable symptomatic
hypoglycaemia
4 (1.8) 7 (3.2)
Relative hypoglycaemia 4 (1.8) 9 (4.2)
Total number of hypoglycaemic
events, n (%)
275 902
Severe hypoglycaemia 0 5 (0.6)
Documented symptomatic
hypoglycaemia
65 (23.6) 292 (32.4)
Asymptomatic hypoglycaemia 190 (69.1) 581 (64.4)
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34.8% at week 5213 and 16.7% at week 156; corresponding values for
participants in the GLIM+MET group were 14.8% at week 52 and
3.2% at week 156.
The mean (standard deviation) duration of exposure throughout
the 156-week treatment period regardless of rescue was 902.0
(344.5) days in the DAPA+SAXA+MET group and 903.0 (338.5) days
in the GLIM+MET group.
Table 2 summarizes the AEs, hypoglycaemic events and urinary
tract infection AEs of special interest during the 156-week treatment
period. None of the participants had any confirmed diabetic
ketoacidosis AEs.
A greater percentage of participants with any urinary tract infec-
tion AE were in the DAPA+SAXA+MET group (17.6%) than in the
GLIM+MET group (11.1%), and such AEs were more common in
women than in men, regardless of group. Table S5 shows the most
common AEs reported with a frequency of ≥5% in either group.
3.2 | MRI substudy
Baseline mean results for liver fat, VAT and SAT were similar for par-
ticipants in the DAPA+SAXA+MET group (14.30%, 3.64 L and 4.71 L,
respectively) compared with the GLIM+MET group (13.71%, 2.92 L
and 4.14 L, respectively). At week 122, treatment with DAPA+SAXA
+MET was associated with greater adjusted mean reductions from
baseline in liver fat and VAT and SAT volumes (adjusting for baseline
value) than treatment with GLIM+MET (LS mean difference from
GLIM+MET 4.89%, 0.41 L and 0.44 L, respectively; nominal P
values ≤ 0.008 [Figure 3A-C]). The mean liver fat and VAT and SAT
volumes at week 122 had relative reductions from baseline of 32%,
10% and 9%, respectively, in the DAPA+SAXA+MET group, deter-
mined as follows: (mean week-122 result  mean baseline result)/
mean baseline result. MRI results at week 122 were consistent with
those at week 52.14 Of the 35 participants in the DAPA+SAXA+MET
group and the 24 participants in the GLIM+MET group with baseline
and week-52 liver fat results, 18 (51.4%) and six (25%), respectively,
were considered responders at week 52 (ie, had relative liver fat
reduction from baseline of at least 30% at week 52).
Mean baseline ALT and AST levels, respectively, were 27.2 and
20.5 U/L in the DAPA+SAXA+MET group, and 29.8 and 23.6 U/L in
the GLIM+MET group (Table S1). LS mean body weight and mean
ALT level reductions from baseline observed at week 52 (4.50 kg
[n = 46]; 5.55 U/L [n = 44]) were sustained to week 156 (4.36 kg
[n = 46]; 7.34 U/L [n = 41]) in the DAPA+SAXA+MET group. Par-
ticipants in the DAPA+SAXA+MET group had greater adjusted mean
decreases from baseline at weeks 52 and 156 in total body weight
(Figure 3D) and at week 52 in HbA1c (Figure S3) compared with
patients in the GLIM+MET group. Mean baseline FIB-4 scores were
<1.45 in both groups, indicative of an absence of advanced fibrosis,
and mean FIB-4 scores were consistent throughout 156 weeks. Mean
changes from baseline in ALT and AST levels over 156 weeks for
DAPA+SAXA+MET and GLIM+MET are shown in Figure S4.
Figure S5 shows pre- and post-treatment liver fat (PDFF) images
from two patients (one patient from each group).
4 | DISCUSSION
At 156 weeks in this 104-week extension to a 52-week study, there
were greater reductions in HbA1c, body weight and liver enzymes
and greater maintenance of glycaemic control with DAPA+SAXA
+MET than with GLIM+MET. Additionally, a higher adjusted mean
weight gain from baseline at week 156 and a higher proportion of par-
ticipants with hypoglycaemia during the 156-week treatment period
were observed in the GLIM+MET group than in the DAPA+SAXA
+MET group.
In the MRI substudy, there were greater adjusted mean reduc-
tions from baseline in liver fat and adipose tissue volume at
122 weeks with DAPA+SAXA+MET than with GLIM+MET. These
data provide evidence of the long-term durability of treatment
TABLE 2 (Continued)
DAPA+SAXA+MET (N = 227) GLIM+MET (N = 216)
Probable symptomatic
hypoglycaemia
4 (1.5) 12 (1.3)
Relative hypoglycaemia 11 (4.0) 16 (1.8)
Note: Safety was analysed according to the treated participants dataset, which comprised all participants who received ≥1 dose of the double-blinded
study drug during the 52-week treatment period. Participants were included in the treatment group to which they were randomized, except if they
received a different treatment for the entire course of participation in the treatment period. There were five events of hypoglycaemia episodes reported
for the DAPA+SAXA+MET group, for which no symptoms or glucose level was recorded. Hypoglycaemic events were categorized using class of events
following American Diabetes Association 2005 recommendations.15 Percentages are based on the number of participants in the treated participants
dataset, except for event level, where percentages are based on total events of hypoglycaemia.
Abbreviations: AE, adverse event; DAPA, dapagliflozin; GLIM, glimepiride; IP, investigational product; MET, metformin; N, number of participants in the
treatment group; SAE, serious adverse event; SAXA, saxagliptin; UTI, urinary tract infection.
aParticipants with multiple events in the same category are counted only once in that category. Participants with events in more than one category are
counted once in each of those categories.
bEvents recorded by the investigators are included in this category. All other categories exclude hypoglycaemic events not reported as SAEs.
cAEs coded using the Medical Dictionary for Regulatory Activities version 22.0.
FRÍAS ET AL. 7
F IGURE 3 Adjusted mean change from baseline at weeks 52 and 122 in (A) liver fat (proton density fat fraction [PDFF]), (B) visceral adipose
tissue (VAT) volume, (C) subcutaneous adipose tissue (SAT) volume and (D) adjusted mean change from baseline at weeks 52 and 156 in total
body weight (randomized analysis set for magnetic resonance imaging substudy). Nominal P value for difference versus glimepiride (GLIM) plus
metformin (MET) in least-squares mean change from baseline at weeks 52 (analysis of covariance [ANCOVA], except mixed model of repeated
measures [MMRM] for total body weight) and 122 or 156 (MMRM), before rescue and treatment discontinuation, adjusting for baseline value.
The mean liver fat and VAT and SAT volumes at week 122 had relative reductions from a baseline of 32%, 10% and 9%, respectively, in the
dapagliflozin (DAPA)+ saxagliptin (SAXA)+MET group. The relative reductions are based on the unadjusted mean values at baseline and week
122. MMRM includes patients with both baseline value and ≥1 post-baseline value for the variable. ANCOVA includes patients with both
baseline and week 52 results for the variable. Δ, least-squares mean difference from GLIM+MET; CI, confidence interval; n, number of patients
included in the analysis
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response in patients with T2D, showing that in addition to improving
metabolic control, DAPA+SAXA+MET also reduces liver fat and asso-
ciated markers of liver inflammation.
Many patients with poorly controlled T2D have steatosis or some
degree of steatohepatitis.16,17 Our MRI substudy results showed that
treatment with DAPA+SAXA+MET was associated with greater
adjusted mean decreases in liver fat (with 32% relative reduction in
means) and SAT and VAT volumes from baseline at week 122 com-
pared with treatment with GLIM+MET. Results were consistent with
decreases at week 52. Other studies support the reduction in liver fat
content with DAPA that we observed.18,19 A study on body fat con-
tent and distribution (whole body, SAT, VAT and liver) that addressed
effects of DAPA in combination with exenatide is largely consistent
with the present data, although numeric reductions in liver fat percent
units were not statistically significant.20
There is a strong association of NAFLD with T2D, and its pres-
ence increases the worsening of liver-related complications as well as
hepatic insulin resistance.21 Given that approximately 70% of patients
with T2D have NAFLD,16,22 interventions that can mitigate the risk,
halt the progression or lessen the impact of liver disease would be
valuable additions to the treatment regimens of most patients with
T2D. NAFLD sometimes involves elevated ALT levels.23 At 156 weeks
in both the MRI substudy and main study, there were greater mean
decreases from baseline in ALT levels in the DAPA+SAXA+MET
group versus the GLIM+MET group.
Overall, our results demonstrate that DAPA+SAXA+MET offers
several advantages over GLIM+MET because of greater overall
glycaemic durability, HbA1c reduction, lower hypoglycaemia risk and
improvement in metabolic profile as shown by weight loss and
improvements in liver fat, adipose tissue volumes and liver enzyme
levels over an extended time period.
Although there are no clinical studies showing the impact of liver
fat and adipose tissue volume reductions on long-term metabolic
health and clinical outcomes in patients with T2D, there is some clini-
cal evidence suggesting that a reduction of >30% in liver fat at
72 weeks is associated with a statistically significant and clinically rel-
evant histological response in patients with nonalcoholic
steatohepatitis.24,25 In a post hoc analysis of the present dataset for
the MRI substudy, mean changes from baseline in HbA1c results were
presented at several timepoints throughout the 156-week treatment
period by responders and “less responders” for each group, where a
responder was defined as a participant who had a relative reduction in
liver fat (PDFF %) from baseline at week 52 of ≥30% and “less
responders” had a relative reduction of <30%, no change or a relative
increase. These results did not suggest a prediction of long-term
glycaemic effects based on liver fat results (data not shown). Investi-
gation of whether the improvements in indicators of liver health that
we observed in the present study are associated with improvements
in clinical outcomes would require larger and longer studies that are
specifically designed to answer this question.
In a 4-year study, DAPA added to MET showed greater durability
of glycaemic control than glipizide plus MET treatment, with less
hypoglycaemia and greater reductions in body weight and SBP.12
Combining drugs with complementary mechanisms of action has been
postulated to possibly maintain long-term glycaemic control.26 How-
ever, the results of the present study do not necessarily support that
the combination per se of DAPA+SAXA+MET preserves β-cell func-
tion to any greater extent than the individual drugs, only that it offers
benefits over GLIM+MET. Further studies would be needed to
explore this possibility. A rationale for early combination therapy with
DAPA+SAXA+MET derives from complementary mechanisms of
action involving insulin-independent durable reductions in HbA1c,
SBP and body weight with DAPA, glucose-dependent insulin secre-
tion with SAXA4 and insulin sensitization with MET.27 Although there
are adherence benefits to monotherapy,28 aggressive early interven-
tion with a fixed-dose combination4 of DAPA and SAXA could
improve adherence compared with administering these drugs
separately.
Durable glycaemic control is a cornerstone of long-term T2D
management. Our results demonstrate that more participants receiv-
ing DAPA+SAXA+MET were able to maintain durability of glycaemic
response than those receiving GLIM+MET. In the short term, the dif-
ference between treatment groups in adjusted mean changes from
baseline in HbA1c, particularly the increase between weeks 16 and
28 in the GLIM group, may have been attributable to hypoglycaemia
and downtitration of GLIM. After week 28, the increases in adjusted
mean changes from baseline in HbA1c appeared similar between the
two study groups, which supports the progressive nature of T2D and
the increased efficacy of the DAPA+SAXA combination versus GLIM.
At week 156, DAPA+SAXA+MET was associated with greater mean
reductions from baseline compared with GLIM+MET in HbA1c, body
weight and serum liver enzyme levels.
The sudden increase in the number of participants in both treat-
ment groups who required rescue therapy around week 56 was most
likely protocol-driven, related to the change from FPG to HbA1c
results at week 52 determining whether rescue medication should be
given (ie, the requirement for rescue being more easily met after
week 52).
Overall, the safety and tolerability profile of DAPA+SAXA
+MET over 156 weeks was generally consistent with that
observed over 52 weeks13 and the established profiles of the indi-
vidual components.9,29
The present study has several limitations. Although this study
included participants of different races, 90% and 100% of the popula-
tion were White in the study and the MRI substudy, respectively. A
more diverse ethnic mix and populations comprising the elderly and
those vulnerable to hypoglycaemia remains to be explored. Further-
more, GLIM was uptitrated only during the initial 12 weeks of the
study to achieve a stable and maximum dose, but some participants
could have benefited from further uptitration during the study. Finally,
almost 12% of the participants who entered the 104-week extension
period dropped out of the study and did not complete the extension
period. Strengths of the study include the fact that it was long-term
(3 years), with double-blinding that continued throughout the exten-
sion period, providing a comprehensive evaluation of liver fat and adi-
pose tissue distribution over 122 weeks.
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In conclusion, the present results indicate that glycaemic control
and favourable metabolic benefits and efficacy are better maintained
with DAPA+SAXA+MET compared with GLIM+MET in patients with
T2D, with a safety profile consistent with that of the individual
components.
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